Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | SEE REMARKS | February 04, 2019 | February 06, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PUMA BIOTECHNOLOGY, INC.
Report date February 04, 2019 · Filed February 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 31,957 |
Reported balance
After 2019-02-04 transaction · row 1
1 source rowRow 1 · 2019-02-04 · Sale · Disposed 87 · Balance 31,957 F1: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2019 Filed Feb 6, 2019 21:38 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 87 | $27.64 | $2,404.71 |
DisclosureSEC source: 0001209191-19-007747 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,957 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:51 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 713 | $24.80 | $17,682.40 |
DisclosureSEC source: 0001209191-19-005185 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,044 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 22:16 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,210 | $20.67 | $25,010.70 |
DisclosureSEC source: 0001209191-19-002102 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,757 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:59 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,239 | $22.77 | $28,212.03 |
DisclosureSEC source: 0001209191-18-060914 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,967 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 13, 2017 to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 21:07 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 610 | $51.95 | $31,689.50 |
DisclosureSEC source: 0001209191-18-043768 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,206 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:08 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,211 | $53.00 | $64,183.00 |
DisclosureSEC source: 0001209191-18-035228 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,816 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 13, 2017 to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 11, 2018 Filed Feb 13, 2018 23:00 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 14,000 | $0.00 Strike: $60.85 | $0.00 |
DisclosureSEC source: 0001209191-18-009708 · doc4.xml · derivative · entry 2 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: COMMON STOCK · 14,000 shares Expires 2028-02-10 F2 · derivative.exercise_date: The vesting commencement date ("Vesting Commencement Date") of the option is January 1, 2018. The option vests (i) with respect to one-third (1/3rd) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option on each monthly anniversary of the Vesting Commencement Date thereafter, subject to Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| February 11, 2018 Filed Feb 13, 2018 23:00 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009708 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,027 F1 · shares: Represents Restricted Stock Units which vest (i) with respect to one-third (1/3rd) of the shares subject thereto on the first anniversary of the vesting commencement date of January 1, 2018 ("Vesting Commencement Date") and (ii) with respect to 1/36th of the shares subject thereto on each monthly anniversary of the Vesting Commencement Date thereafter, subject to Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 21:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 669 | $92.85 | $62,116.65 |
DisclosureSEC source: 0001209191-18-005135 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2017 to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 22, 2018 Filed Aug 2, 2018 20:33 UTC Amendment | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 669 | $92.85 | $62,116.65 |
DisclosureSEC source: 0001209191-18-044965 · doc4a.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2017 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · acquired: This amended Form 4 is filed solely for the purpose of correcting an administrative error in column 4 reporting securities as acquired, instead of disposed of, as reported on the Form 4 filed January 24, 2018. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:06 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,322 | $105.46 | $139,424.20 |
DisclosureSEC source: 0001209191-17-063874 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,696 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 13, 2017 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.3696 to $105.7000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 21:14 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 662 | $95.15 | $62,991.09 |
DisclosureSEC source: 0001209191-17-046090 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,018 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in two transactions with one transaction pricing at $95.151 and the other transaction pricing at $95.701. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price set forth in this footnote. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 21:00 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036835 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,680 F1 · shares: Represents Restricted Stock Units which vest in six substantially equal installments on each six-month anniversary of the Vesting Commencement Date of May 31, 2017, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 21:41 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 31,500 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0001209191-17-012744 · doc4.xml · derivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: COMMON STOCK · 31,500 shares Expires 2027-02-15 F1 · derivative.exercise_date: The vesting commencement date ("Vesting Commencement Date") of the option is February 16, 2017. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to Reporting Person's continued service with the Issuer. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:53 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 820 | $33.24 | $27,252.78 |
DisclosureSEC source: 0001209191-17-005352 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,680 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.90 to $33.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 14, 2016 Filed Oct 15, 2016 01:18 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-145980 · doc4.xml · nonDerivative · entry 1 EYLER CHARLES R · CIK 0001358246 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: Represents Restricted Stock Units which vest in six substantially equal installments on each six-month anniversary of the Vesting Commencement Date of July 19, 2016, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.